# Intelligent Bio Solutions Inc. (INBS)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $12M  
**Price:** $2.31 (-1.70%)

> Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions. Its primary offering, the Intelligent Fingerprinting Drug Testing Solution, utilizes fingerprint sweat analysis to detect recent use of common workplace drugs such as opiates, cocaine, methamphetamine, cannabis, benzodiazepines, and marijuana. This portable, hygienic, and cost-effective system enables sample collection in seconds and delivers results in under ten minutes, making it ideal for safety-critical environments. The company serves diverse industries including construction, mining, manufacturing, engineering, transport, logistics, drug treatment, law enforcement, and forensics, with accounts spanning multiple countries. Additionally, Intelligent Bio Solutions Inc. develops a Saliva Glucose Biosensor Platform aimed at real-time monitoring and diagnostic tests for chronic disease management. Operating through segments like Intelligent Fingerprinting Products and the biosensor platform, it focuses on advancing portable drug screening and biosensor technologies across regions including the United Kingdom, Asia Pacific, Americas, and rest of world. Founded in 2016 and headquartered in New York, New York, the company plays a key role in the growing market for non-invasive medical diagnostics.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $3M | $1M | -$11M | -$11M | — |
| 2024 | $3M | $1M | -$10M | -$10M | — |
| 2023 | $1M | $326,668 | -$13M | -$11M | — |
| 2022 | $437,146 | — | -$8M | -$8M | — |
| 2021 | $2M | — | -$6M | -$7M | — |
| 2020 | $188,744 | — | -$3M | -$3M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $8M | $5M | $3M | $1M | — |
| 2024 | $14M | $6M | $8M | $6M | — |
| 2023 | $10M | $7M | $4M | $2M | — |
| 2022 | $12M | $6M | $7M | $8M | — |
| 2021 | $22M | $7M | $15M | $13M | — |
| 2020 | $2M | $8M | -$5M | $427,273 | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $231,838 | -$10M |
| 2024 | -$10M | $221,426 | -$10M |
| 2023 | -$7M | — | — |
| 2022 | -$3M | — | — |
| 2021 | -$11M | — | — |
| 2020 | -$498,618 | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/INBS)